{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:59:19Z","timestamp":1770814759175,"version":"3.50.1"},"reference-count":49,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T00:00:00Z","timestamp":1438041600000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Mephedrone is a stimulant drug chemically related to amphetamine, with effects similar to those of amphetamine and cocaine. This study aims to analyse fatalities following ingestion of mephedrone in the UK amongst 16\u2010 to 24\u2010year\u2010olds in 2009\u20132013, providing an update on data presented at the 2nd International Conference on Novel Psychoactive Substances.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A literature search was undertaken to identify published information on pharmacology, toxicity and fatalities associated with mephedrone. Fatalities involving mephedrone were extracted from the National Programme on Substance Abuse Deaths database, which receives information on drug\u2010related deaths from coroners in the UK and Islands and other data suppliers. Selection criteria are as follows: deceased aged 16\u201324\u2009years at time of death and mephedrone directly implicated in the cause of death and\/or mentioned in the coroner's verdict.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty cases met the study criteria, and when known, all were of White ethnicity, most (85%) had a history of drug use and 73% were male. Two\u2010thirds (63%) were accidental poisonings. Mephedrone was used with other substances in most cases (87%); other substances were implicated in 60% of deaths.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Mephedrone use can have potentially fatal consequences, especially in combination with other substances. Deaths from its use in the 16\u201324\u2009years' age group continue to occur in the UK, despite it being a controlled drug. Health professionals and potential consumers should be alert to this risk. Copyright \u00a9 2015 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2423","type":"journal-article","created":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T07:15:45Z","timestamp":1438067745000},"page":"225-232","source":"Crossref","is-referenced-by-count":53,"title":["Deaths of individuals aged 16\u201324\u2009years in the UK after using mephedrone"],"prefix":"10.1002","volume":"30","author":[{"given":"Barbara","family":"Loi","sequence":"first","affiliation":[{"name":"National Programme on Substance Abuse Deaths (NPSAD), St George's University of London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Martin","family":"Corkery","sequence":"additional","affiliation":[{"name":"National Programme on Substance Abuse Deaths (NPSAD), St George's University of London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugh","family":"Claridge","sequence":"additional","affiliation":[{"name":"National Programme on Substance Abuse Deaths (NPSAD), St George's University of London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Goodair","sequence":"additional","affiliation":[{"name":"National Programme on Substance Abuse Deaths (NPSAD), St George's University of London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Chiappini","sequence":"additional","affiliation":[{"name":"National Programme on Substance Abuse Deaths (NPSAD), St George's University of London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Gimeno Clemente","sequence":"additional","affiliation":[{"name":"National Programme on Substance Abuse Deaths (NPSAD), St George's University of London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Schifano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,7,28]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"Advisory Council on the Misuse of Drugs on Consideration of the Cathinones","author":"Advisory Council on the Misuse of Drugs (ACMD)","year":"2010"},{"key":"e_1_2_8_3_1","volume-title":"Consideration of the Novel Psychoactive Substances (\u2018Legal Highs\u2019)","author":"Advisory Council on the Misuse of Drugs (ACMD)","year":"2011"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.02.011"},{"key":"e_1_2_8_5_1","first-page":"355","volume-title":"Pharmacology","author":"Corkery JM","year":"2012"},{"key":"e_1_2_8_6_1","unstructured":"CorkeryJ ClaridgeH LoiB GoodairC SchifanoF.2014.Drug\u2010related deaths in the UK: annual report 2013. Drug\u2010related deaths reported by coroners in England Wales Northern Ireland Guernsey Jersey and the Isle of Man; police forces in Scotland; & the Northern Ireland Statistics and Research Agency\u2014annual report January\u2013December 2012. International Centre for Drug Policy: St George's University of London. Available athttp:\/\/www.sgul.ac.uk\/research\/projects\/icdp\/our\u2010work\u2010programmes\/pdfs\/National%20Programme%20on%20Substance%20Abuse%20Deaths%20\u2010%20Annual%20Report%202013%20on%20Drug\u2010related%20Deaths%20in%20the%20UK%20January\u2010December%202012%20PDF.pdf(Accessed 7 March 2014)"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bks094"},{"key":"e_1_2_8_8_1","unstructured":"Council of the European Union.2011.Council conclusions on new psychoactive substances. Available athttp:\/\/www.consilium.europa.eu\/uedocs\/cms_data\/docs\/pressdata\/en\/jha\/126879.pdf(Accessed 3 June 2014)"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00538-5"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.312"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1258\/rsmmsl.46.1.37"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/34.3.162"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/emj.2011.112920"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c1690"},{"key":"e_1_2_8_15_1","unstructured":"EMCDDA.2011.Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances May 2011 European Monitoring Centre for Drugs and Drug Addiction: Lisbon. Available athttp:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_116646_EN_TDAK11001ENC_WEB\u2010OPTIMISED%20FILE.pdf(Accessed 7 March 2014)"},{"key":"e_1_2_8_16_1","unstructured":"Europol\u2010EMCDDA.2010.Europol\u2010EMCDDA Joint Report on a new psychoactive substance: 4\u2010methylmethcathinone (mephedrone) March 2010 European Monitoring Centre for Drugs and Drug Addiction: Lisbon. Available athttp:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_132203_EN_2010_Mephedrone_Joint%20report.pdf(Accessed 7 March 2014)"},{"key":"e_1_2_8_17_1","unstructured":"GhodseH CorkeryJ AhmedK NaidooV OyefesoA SchifanoF.2010.Drug\u2010related deaths in the UK: annual report 2010. Drug\u2010related deaths reported by coroners in England Wales Northern Ireland Guernsey Jersey and the Isle of Man; police forces in Scotland; & the Northern Ireland Statistics and Research Agency\u2014annual report January\u2013December 2009. London: International Centre for Drug Policy: St George's University of London. 24 August 2010. Available athttp:\/\/www.sgul.ac.uk\/research\/projects\/icdp\/pdf\/np\u2010SAD%2011th%20annual%20report%20Final.pdf(Accessed 10 March 2014)"},{"key":"e_1_2_8_18_1","unstructured":"GhodseH CorkeryJ ClaridgeH GoodairC SchifanoF.2013.Drug\u2010related deaths in the UK: Annual Report 2012. Drug\u2010related deaths reported by Coroners in England Wales Northern Ireland Guernsey Jersey and the Isle of Man; Police forces in Scotland; & the Northern Ireland Statistics and Research Agency \u2013 Annual Report January\u2013December 2011. London: International Centre for Drug Policy: St George's University of London. 2013. Available athttp:\/\/www.sgul.ac.uk\/research\/projects\/icdp\/our-work-programmes\/substance-abuse-deaths(Accessed 10 March 2014)"},{"key":"e_1_2_8_19_1","volume-title":"Drug Misuse: Findings from the 2012 to 2013 Crime Survey for England and Wales","author":"Home Office","year":"2013"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/emj.2010.096636"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(90)90057-9"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1992.tb00434.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.01998.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/anatox\/35.3.188"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.5042\/daat.2010.0123"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm050797a"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60559-4"},{"key":"e_1_2_8_28_1","volume-title":"Mephedrone: Use of Mephedrone (M\u2010Cat, Meow) in Middlesbrough","author":"Newcombe R","year":"2009"},{"key":"e_1_2_8_29_1","unstructured":"Psychonaut Web Mapping Research Group.2009.Mephedrone Report. Institute of Psychiatry: King's College London. Available athttp:\/\/www.psychonautproject.eu\/documents\/reports\/Mephedrone.pdf(Accessed 7 March 2014)"},{"key":"e_1_2_8_30_1","unstructured":"Psychonaut Web Mapping Research Project.2010.Institute of Psychiatry: King's College London. Available athttp:\/\/www.psychonautproject.eu\/documents\/reports\/Psychonaut_Project_Executive_Summary.pdf(Accessed 7 March 2014)"},{"key":"e_1_2_8_31_1","unstructured":"RicciV MartinottiG GelfoF et al.2011.Chronic ketamine use increases serum levels of brain\u2010derived neurotrophic factor. doi:10.1007\/s00213\u2010010\u20102121\u20103."},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1730-5"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105056660"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000279302"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-010-2070-x"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318266c70c"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.02145.x"},{"key":"e_1_2_8_38_1","unstructured":"SumnallH WoodingO.2009.Mephedrone: an update on current knowledge. Centre for Public Health: Liverpool John Moores University. Available athttp:\/\/www.cph.org.uk\/?s=mephedrone&post_type=publication(Accessed 7 March 2014)"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2010.07.014"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-008-0811-1"},{"key":"e_1_2_8_41_1","unstructured":"United Nations Office on Drugs and Crime (UNODC).2013.World Drug Report 2013. Available at:http:\/\/www.unodc.org\/wdr\/en\/nps.html(Accessed 3 June 2014)"},{"key":"e_1_2_8_42_1","unstructured":"WinstockA.2013.Mixmag's global survey: the results.264:76\u201381. Available athttp:\/\/www.mixmag.net\/words\/features\/mixmags\u2010global\u2010drug\u2010survey\u2010the\u2010results(Accessed 7 March 2014)"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c1605"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62021-1"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03130.x"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-010-0018-5"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcs107"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/emermed-2011-200747"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1671"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hct183"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2423","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T07:49:57Z","timestamp":1696405797000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1002\/hup.2423"],"URL":"https:\/\/doi.org\/10.1002\/hup.2423","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}